| Current and emerging strategies for management of myelodysplastic syndromes |
|
Blood reviews |
Myelodysplastic Syndromes (MDS) |
| Validation of International Working Group response criteria in higher-risk myelodysplastic syndromes: A report on behalf of the MDS Clinical Research Consortium |
|
Cancer Medicine |
Myelodysplastic Syndromes (MDS) |
| Paroxysmal nocturnal hemoglobinuria: role of the complement system, pathogenesis, and pathophysiology |
|
Journal of Managed care and specialty pharmacy |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Paroxysmal nocturnal hemoglobinuria: patient journey and burden of disease |
|
Journal of Managed care and specialty pharmacy |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Paroxysmal nocturnal hemoglobinuria: current treatments and unmet needs |
|
Journal of Managed care and specialty pharmacy |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| One-year outcomes from a phase 3 randomized trial of ravulizumab in adults with paroxysmal nocturnal hemoglobinuria who received prior eculizumab |
|
European Journal of Haematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Frequency and perturbations of various peripheral blood cell populations before and after eculizumab treatment in paroxysmal nocturnal hemoglobinuria |
|
Blood, cells, molecules & diseases |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Survival following relapse after allogeneic hematopoietic cell transplantation for acute leukemia and myelodysplastic syndromes |
|
Hematology/oncology and stem cell therapy |
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) |
| Existing agents, novel agents, or transplantation for high-risk MDS |
|
Hematology. American Society of Hematology. Education Program |
Myelodysplastic Syndromes (MDS) |
| Therapy for lower-risk MDS |
|
Hematology. American Society of Hematology. Education Program |
Myelodysplastic Syndromes (MDS) |
